A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.

Trial Profile

A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2014

At a glance

  • Drugs Amdoxovir (Primary) ; Lopinavir/ritonavir; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RFS Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2014 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top